Search research articles
Contact Us
Filters
Showing results (221-230 of 304) with videos related to
Page
of 31
Sort By:
JTO Clinical and Research Reports
|
June 20, 2022
Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report
Yuanbin Chen, Luis Paz-Ares, Niels Reinmuth, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 27, 2018
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
Scott Gettinger, Matthew D Hellmann, Laura Q M Chow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2021
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma
D Ross Camidge, Daniel Morgensztern, Rebecca S Heist, et al.
Clinical Lung Cancer
|
January 19, 2025
Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial
Jonathan W Goldman, Alejandro Martinez Bueno, Christophe Dooms, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 30, 2016
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Scott Gettinger, Naiyer A Rizvi, Laura Q Chow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2018
Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study
Edward S Kim, Karen Kelly, Luis G Paz-Ares, et al.
Blood Cancer Discovery
|
November 9, 2022
ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic Leukemia
Rohan Kodgule, Joshua W Goldman, Alexander C Monovich, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 23, 2025
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report
Xiuning Le, Christina Baik, Byoung Chul Cho, et al.
JTO Clinical and Research Reports
|
January 10, 2022
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC
D Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, et al.
JTO Clinical and Research Reports
|
November 25, 2022
The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study
David J Benjamin, Shuai Chen, Joanna B Eldredge, et al.
Page
of 31
Search research articles
Search
Showing results (221-230 of 304) with videos related to
Sort By:
Page
of 31
JTO Clinical and Research Reports
|
June 20, 2022
Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report
Yuanbin Chen, Luis Paz-Ares, Niels Reinmuth, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 27, 2018
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
Scott Gettinger, Matthew D Hellmann, Laura Q M Chow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2021
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma
D Ross Camidge, Daniel Morgensztern, Rebecca S Heist, et al.
Clinical Lung Cancer
|
January 19, 2025
Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial
Jonathan W Goldman, Alejandro Martinez Bueno, Christophe Dooms, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 30, 2016
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Scott Gettinger, Naiyer A Rizvi, Laura Q Chow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2018
Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study
Edward S Kim, Karen Kelly, Luis G Paz-Ares, et al.
Blood Cancer Discovery
|
November 9, 2022
ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic Leukemia
Rohan Kodgule, Joshua W Goldman, Alexander C Monovich, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 23, 2025
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report
Xiuning Le, Christina Baik, Byoung Chul Cho, et al.
JTO Clinical and Research Reports
|
January 10, 2022
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC
D Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, et al.
JTO Clinical and Research Reports
|
November 25, 2022
The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study
David J Benjamin, Shuai Chen, Joanna B Eldredge, et al.
Page
of 31